

Special Issue

Allogeneic Cell Cancer Immunotherapies

Message from the Guest Editor

Allogeneic immuno-cell therapies are beginning to replace autologous chimeric antigen receptor technologies (CAR-T). The major problem is the recognition of allogeneic cells by the recipient immune system that risks donor cell rejection and graft versus host disease. Given the success of CAR-T for B cell blood cancers, considerable effort is underway to enable single CAR-T products to treat large numbers of patients in a cost-effective way. The ability of gene stem cells to insert CARs into safe harbor sites in the genome and to knock out checkpoint inhibitor genes that prevent tumor destruction is being trialed in animal models and in early-stage clinical trials. These studies are targeted at multiple blood and solid cancers, and also at cells infected with pathological viruses such as HIV and COVID-19. Early progress is encouraging, but the outcome of human clinical trials remains essential to evaluate the safety and efficacy of these new allogeneic cell therapy approaches.

Guest Editor

Prof. Alan Trounson

Hudson Institute of Medical Research, Monash University and Cartherics Pty. Ltd., Clayton, Australia

Deadline for manuscript submissions

closed (20 October 2021)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/59422

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).